Impact of screening on clinicopathological features and treatment for invasive breast cancer: results of two national surveys.
Fiche publication
Date publication
août 2015
Journal
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry
Tous les auteurs :
Cutuli B, Dalenc F, Cottu PH, Gligorov J, Guastalla JP, Petit T, Amrate A
Lien Pubmed
Résumé
Several studies showed a breast cancer downstaging due to screening. A first national survey was conducted in France in 2001-2002 to evaluate in the current clinical practice the clinicopathological features and treatments of 1049 firstly operated breast cancers. In order to assess the impact of the national screening program implemented in all regions in France in 2004, a new survey was performed in 2007-2008.
Mots clés
Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, therapeutic use, Antineoplastic Agents, therapeutic use, Breast Neoplasms, epidemiology, Carcinoma, Ductal, Breast, epidemiology, Carcinoma, Lobular, epidemiology, Chemotherapy, Adjuvant, statistics & numerical data, Female, France, epidemiology, Health Surveys, Humans, Lymph Node Excision, statistics & numerical data, Mass Screening, Mastectomy, statistics & numerical data, Mastectomy, Segmental, statistics & numerical data, Middle Aged, Neoplasm Grading, Neoplasm Staging, Prospective Studies, Radiotherapy, Adjuvant, Receptor, ErbB-2, metabolism, Receptors, Estradiol, metabolism, Receptors, Progesterone, metabolism, Sentinel Lymph Node Biopsy, statistics & numerical data, Trastuzumab, Young Adult
Référence
Cancer Radiother. 2015 Aug;19(5):295-302